other material
confidence high
sentiment neutral
materiality 0.50
Matinas BioPharma closes $1.65M second tranche of Series C preferred & warrant offering
Matinas BioPharma Holdings, Inc.
- Second closing on April 8, 2025 raised $1.65M from sale of 1,650 Series C Convertible Preferred shares.
- Total offering raises $3.3M; preferred initially convertible into up to 5.63M common shares, warrants for 11.26M additional shares.
- Securities issued without registration under Section 4(a)(2) and Regulation D; proceeds for general corporate purposes.
- First closing of 1,650 shares occurred on February 13, 2025.